Biotechnology Core Laboratory National Institutes of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA.
Department of Chemistry and Biochemistry, College of Science, George Mason University, Fairfax, VA 22030, USA.
Cells. 2021 Jul 2;10(7):1667. doi: 10.3390/cells10071667.
The HEK293 cell line has earned its place as a producer of biotherapeutics. In addition to its ease of growth in serum-free suspension culture and its amenability to transfection, this cell line's most important attribute is its human origin, which makes it suitable to produce biologics intended for human use. At the present time, the growth and production properties of the HEK293 cell line are inferior to those of non-human cell lines, such as the Chinese hamster ovary (CHO) and the murine myeloma NSO cell lines. However, the modification of genes involved in cellular processes, such as cell proliferation, apoptosis, metabolism, glycosylation, secretion, and protein folding, in addition to bioprocess, media, and vector optimization, have greatly improved the performance of this cell line. This review provides a comprehensive summary of important achievements in HEK293 cell line engineering and on the global engineering approaches and functional genomic tools that have been employed to identify relevant genes for targeted engineering.
HEK293 细胞系已成为生物治疗药物的生产商。除了易于在无血清悬浮培养中生长和可转染外,该细胞系最重要的特征是其源自人类,这使其适合生产用于人类使用的生物制品。目前,HEK293 细胞系的生长和生产性能不如非人类细胞系,如中国仓鼠卵巢(CHO)和鼠骨髓瘤 NSO 细胞系。然而,对细胞过程相关基因的修饰,如细胞增殖、凋亡、代谢、糖基化、分泌和蛋白质折叠,以及生物工艺、培养基和载体优化,极大地提高了该细胞系的性能。本文综述了 HEK293 细胞系工程的重要成就,以及全球工程方法和功能基因组工具,这些方法和工具已被用于鉴定相关基因,以进行有针对性的工程改造。